Associated Papers
Potential clinical relevance of rare dihydropyrimidine dehydrogenase genetic variants identified using whole-exome NextGen sequencing in cancer patients with severe fluoropyrimidine toxicity.
Cui E et al.
Cancer Chemotherapy and Pharmacology, 2025
Somatic Mutations Alter Interleukin Signaling Pathways in Grade II Invasive Breast Cancer Patients: An Egyptian Experience.
Nassar A et al.
Current Issues in Molecular Biology, 2022
Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data.
Lanillos J et al.
Npj Genomic Medicine, 2022
In Vitro Assessment of Fluoropyrimidine-Metabolizing Enzymes: Dihydropyrimidine Dehydrogenase, Dihydropyrimidinase, and β-Ureidopropionase.
Hishinuma E et al.
Journal of Clinical Medicine, 2020
Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase.
Shrestha S et al.
Clinical Pharmacology and Therapeutics, 2018
Novel Deleterious Dihydropyrimidine Dehydrogenase Variants May Contribute to 5-Fluorouracil Sensitivity in an East African Population.
Elraiyah T et al.
Clinical Pharmacology and Therapeutics, 2017
De novo mutations in moderate or severe intellectual disability.
Hamdan FF et al.
Plos Genetics, 2014
Severe fluoropyrimidine-related toxicity: clinical implications of DPYD analysis and UH2/U ratio evaluation.
Giorgio E et al.
Cancer Chemotherapy and Pharmacology, 2011
Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?
Ciccolini J et al.
Clinical Colorectal Cancer, 2010
Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals.
Seck K et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2005
Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.
Lee A et al.
Clinical Advances in Hematology & Oncology : H&o, 2004
Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity.
Ezzeldin H et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2003
Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil.
Johnson MR et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 1999